Last reviewed · How we verify
Valsartan/aliskiren
This combination blocks two pathways in the renin-angiotensin-aldosterone system: valsartan blocks angiotensin II receptors while aliskiren inhibits renin, reducing blood pressure through dual inhibition.
This combination blocks two pathways in the renin-angiotensin-aldosterone system: valsartan blocks angiotensin II receptors while aliskiren inhibits renin, reducing blood pressure through dual inhibition. Used for Hypertension.
At a glance
| Generic name | Valsartan/aliskiren |
|---|---|
| Sponsor | Novartis |
| Drug class | Angiotensin II receptor blocker + direct renin inhibitor combination |
| Target | AT1 receptor (valsartan); renin (aliskiren) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Valsartan is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from binding to AT1 receptors on blood vessels and other tissues, causing vasodilation and reduced aldosterone secretion. Aliskiren is a direct renin inhibitor that blocks the first step of the renin-angiotensin cascade, preventing the conversion of angiotensinogen to angiotensin I. Together, they provide complementary inhibition of this system for enhanced blood pressure reduction.
Approved indications
- Hypertension
Common side effects
- Hyperkalemia
- Dizziness
- Fatigue
- Renal impairment
Key clinical trials
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients (PHASE3)
- Assessment of Renin Inhibition on Insulin Sensitivity, Diastolic Function and Aortic Compliance (NA)
- Aliskiren on Retinal Vasculature Treatment Study (PHASE3)
- Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure (PHASE3)
- A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Valsartan in Hypertensive Non Responders Patients (PHASE3)
- Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients (PHASE2)
- Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Valsartan/aliskiren CI brief — competitive landscape report
- Valsartan/aliskiren updates RSS · CI watch RSS
- Novartis portfolio CI